Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02537431 · ClinicalTrials.gov registry record · Phase 3
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
A Phase 3 study, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 3
- Development phase
- 14
- Enrollment target
NCT02537431: Completed Phase 3 study, sponsored by Kyowa Kirin.
NCT02537431 is a Phase 3 study that has completed, run by Kyowa Kirin. The registered enrollment target is 14 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02537431, a Phase 3 study, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14 participants
- Enrollment target
Study Summary
The primary objective of this study is to establish the effect of KRN23 treatment on improvement in XLH-associated osteomalacia as determined by osteoid volume (osteoid volume/bone volume, OV/BV).
Primary Outcome
OV/BV: percent of a given volume of bone tissue that consists of unmineralized bone (osteoid).
Interventions
- BIOLOGICAL burosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-12-23 |
| Est. Completion | 2018-12-13 |
| Phase | Phase 3 |
What the finished NCT02537431 record still lists
NCT02537431 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which burosumab is the first listed.
NCT02537431 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02537431 about?
NCT02537431 is a clinical study titled "Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)". The primary objective of this study is to establish the effect of KRN23 treatment on improvement in XLH-associated osteomalacia as determined by osteoid volume (osteoid volume/bone volume, OV/BV).
What is the current status of trial NCT02537431?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 14 participants. The study started on 2015-12-23. Estimated completion is 2018-12-13.
What interventions are being tested in trial NCT02537431?
The interventions under investigation include: burosumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02537431?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02537431's enrollment target sits among peer trials
14 1983rd of 2000 higher than 17 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy